EngineeringtheTILFrontier:BuildingtheInfrastructureforNext-GenerationCellTherapy

The Science of Tumor-Infiltrating Lymphocyte Therapy

The clinical development of tumor-infiltrating lymphocyte therapy was pioneered by Steven Rosenberg at the National Cancer Institute during the late 1980s. His work laid the conceptual and experimental foundation for adoptive cell transfer approaches that leverage endogenous anti-tumor immunity.

Unlike CAR-T cell therapy, which typically involves collecting circulating lymphocytes from peripheral blood, TIL-based therapy requires the surgical extraction of a tumor specimen. This distinction is crucial: the T-cells capable of recognizing tumor-specific antigens are already embedded within the tumor microenvironment.

Tumor-infiltrating lymphocytes represent immune cells that have successfully migrated into the tumor and initiated an anti-tumor response. These cells can be viewed as the immune system’s most specialized responders having already recognized tumor antigens and navigated the suppressive tumor microenvironment.

However, tumors often evade immune destruction by secreting inhibitory cytokines and expressing immune checkpoint ligands that drive T-cell exhaustion. Over time, these molecular signals dampen the cytotoxic function of the infiltrating lymphocytes, allowing tumor progression despite the presence of tumor-reactive immune cells.

TIL therapy aims to reverse this failure of immune persistence.

During treatment, a surgeon removes a portion of the tumor, allowing researchers to isolate these tumor-specific lymphocytes. The cells are then expanded ex vivo into billions of copies before being reinfused into the patient. Because these cells originate from the patient and have already demonstrated tumor recognition, they retain the capacity to home back to metastatic sites and mount a significantly amplified immune response.

This strategy effectively converts a small population of partially exhausted immune cells into a large, therapeutically potent population capable of systemic tumor surveillance.

The manufacturing process begins with the surgical procurement of a tumor lesion typically measuring between 1.5 and 5 centimeters in diameter. Unlike therapies derived from peripheral blood samples, this step introduces significant logistical complexity.

Tumor procurement requires specialized surgical protocols, dedicated collection kits, and carefully controlled cold-chain transport to centralized manufacturing facilities. Once received, the tumor specimen undergoes a series of cellular isolation procedures to extract the infiltrating lymphocyte populations.

These cells are then expanded over approximately 22 days in culture conditions enriched with aldesleukin, a high-dose interleukin-2 therapy commercially known as Proleukin. Interleukin-2 serves as a powerful growth signal that stimulates rapid proliferation of T-cells, enabling the expansion of a small tumor-derived population into a therapeutically viable dose consisting of billions of cells.

Recognizing the central role of IL-2 in this process, Iovance strategically acquired Proleukin to integrate this component into its therapeutic platform. In parallel, the company is developing IOV-3001, a next-generation IL-2 fusion protein designed to preserve immune stimulation while potentially reducing systemic toxicity.

Iovance Biotherapeutics has been one of the more closely scrutinized biotechnology companies over the past two years, largely due to the complex commercial rollout of Amtagvi, a tumor-infiltrating lymphocyte (TIL) therapy approved for the treatment of unresectable metastatic melanoma.

The company faced considerable skepticism following early manufacturing delays and slower-than-expected commercial adoption. Some analysts argued that had Iovance been acquired by a larger pharmaceutical organization earlier in its development cycle, the manufacturing and logistical hurdles associated with TIL therapy may have been mitigated through existing commercial infrastructure. Instead, Iovance undertook the formidable task of building this ecosystem independently.

Encouragingly, the past two quarters have demonstrated measurable progress following initial production bottlenecks and a substantial organizational restructuring. The key question now facing investors and oncologists alike is whether Iovance can sustain this growth trajectory meeting the evident demand for Amtagvi while successfully expanding the TIL platform into additional treatment-resistant malignancies.

While melanoma provided the initial proof of concept, the long-term potential of TIL therapy lies in its application to other solid tumors. Iovance is currently pursuing clinical expansion into several additional indications, including Non-Small Cell Lung Cancer and Endometrial Cancer.

The IOV-LUN-202 Phase 2 trial evaluating TIL therapy in non-small cell lung cancer recently reported a 25.6% objective response rate, with a median duration of response that has not yet been reached after more than two years of follow-up. If subsequent studies confirm these findings, a regulatory submission could potentially enable commercial launch around 2027.

Another particularly intriguing avenue involves combining TIL therapy with PD-1 checkpoint blockade. Checkpoint inhibitors targeting the PD-1 pathway remain the most commercially successful immunotherapies in oncology, with Keytruda alone generating approximately $31.7 billion in global sales during 2025.

Iovance is exploring this synergy through two key programs:

TILVANCE-301: A clinical trial evaluating the combination of pembrolizumab and TIL therapy as a first-line treatment for metastatic melanoma.

IOV-4001: A next-generation TIL product engineered with PD-1 inactivation, currently under evaluation in Phase 2 trials.

Additionally, interim data from the IOV-SAR-201 study in Soft Tissue Sarcoma reported an encouraging 50% objective response rate. Because cancers such as lung and endometrial cancer account for significantly more annual deaths than melanoma, successful expansion into these indications would dramatically increase the addressable market for TIL therapy.

The long-term success of Iovance will ultimately depend on whether TIL therapy can consistently deliver durable responses across a broader range of solid tumors. Nevertheless, the clinical evidence accumulated thus far offers compelling support for the therapeutic potential of adoptive cell transfer.

If these trends continue, TIL therapy may evolve from a specialized melanoma treatment into a foundational modality within the broader landscape of oncology immunotherapy.